Charles Schwab Investment Management Inc. increased its holdings in Accolade, Inc. (NASDAQ:ACCD - Free Report) by 7.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 611,731 shares of the company's stock after purchasing an additional 42,530 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.75% of Accolade worth $2,092,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds also recently bought and sold shares of the business. Pallas Capital Advisors LLC bought a new stake in shares of Accolade in the 4th quarter worth approximately $38,000. Mission Creek Capital Partners Inc. purchased a new stake in Accolade in the third quarter worth $38,000. Wolverine Trading LLC purchased a new stake in Accolade in the third quarter worth $51,000. Point72 Asia Singapore Pte. Ltd. boosted its holdings in Accolade by 1,144.1% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 20,913 shares of the company's stock valued at $81,000 after acquiring an additional 19,232 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new position in Accolade during the 3rd quarter valued at $96,000. Hedge funds and other institutional investors own 84.99% of the company's stock.
Analyst Upgrades and Downgrades
Several research firms have recently commented on ACCD. Raymond James reaffirmed a "market perform" rating on shares of Accolade in a research report on Thursday, January 9th. Needham & Company LLC restated a "hold" rating on shares of Accolade in a report on Wednesday, January 8th. Stifel Nicolaus reaffirmed a "hold" rating and set a $7.03 price objective (down from $8.00) on shares of Accolade in a research report on Thursday, January 9th. Truist Financial lowered Accolade from a "strong-buy" rating to a "hold" rating in a research report on Friday, January 10th. Finally, Morgan Stanley dropped their price target on Accolade from $6.00 to $5.00 and set an "equal weight" rating on the stock in a research report on Tuesday, December 17th. Thirteen analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat, Accolade presently has a consensus rating of "Hold" and a consensus price target of $6.51.
View Our Latest Stock Analysis on Accolade
Accolade Stock Performance
Accolade stock remained flat at $6.99 during mid-day trading on Wednesday. The company's stock had a trading volume of 369,780 shares, compared to its average volume of 1,402,591. Accolade, Inc. has a twelve month low of $3.08 and a twelve month high of $9.67. The company has a quick ratio of 2.63, a current ratio of 2.63 and a debt-to-equity ratio of 0.67. The business has a 50 day simple moving average of $6.94 and a 200 day simple moving average of $5.02. The company has a market capitalization of $573.13 million, a P/E ratio of -3.11 and a beta of 2.18.
Accolade (NASDAQ:ACCD - Get Free Report) last announced its quarterly earnings results on Friday, January 10th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.31) by $0.01. Accolade had a negative net margin of 40.36% and a negative return on equity of 20.74%. Equities research analysts anticipate that Accolade, Inc. will post -1.2 EPS for the current year.
Accolade Company Profile
(
Free Report)
Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and primary care physicians.
Further Reading
Before you consider Accolade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Accolade wasn't on the list.
While Accolade currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
